A Paradigm Shift in Respiratory Syncytial Virus Prevention in Infants
A Paradigm Shift in Respiratory Syncytial Virus Prevention in Infants · 15.06.2026 · III (02)
DOI: 10.62830/mmj3-02-6a ↗Kurz gefasst
Fachartikel in der Zeitschrift A Paradigm Shift in Respiratory Syncytial Virus Prevention in Infants, online erschienen am 15.06.2026. Verfasst von Ashu Sawhney.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) such as bronchiolitis and pneumonia in infants and young children worldwide, with the highest burden occurring during the first six months of life. Infants are particularly susceptible because of their narrow airways, immature immune responses, developing lungs, and decline in maternally derived antibodies, resulting in a high risk of severe bronchiolitis, hypoxia, respiratory failure, hospitalisation, and mortality. India contributes substantially to the global RSV burden, with a significant proportion of RSV-related deaths occurring in community settings before timely access to healthcare. In addition to acute illness, severe RSV infection in infancy is associated with long-term respiratory sequelae, including recurrent wheezing, asthma, and impaired pulmonary function. As effective antiviral therapies remain limited, prevention has become the cornerstone of RSV control. Recent advances in RSV prevention, including long-acting monoclonal antibodies and maternal immunisation, have transformed the preventive landscape. Nirsevimab, a long-acting monoclonal antibody targeting the prefusion F protein of RSV, provides rapid and sustained protection with a single intramuscular dose and has demonstrated substantial reductions in medically attended RSV-LRTIs and RSV-related hospitalisations in both clinical trials and real-world studies. International health organisations and national paediatric bodies now recognise RSV prevention as a major public health priority. These advances represent a paradigm shift in infant RSV prevention with the potential to significantly reduce RSV-associated morbidity, hospitalisation, mortality, and long-term respiratory complications, particularly in high-burden settings such as India.
Zitieren
APA
Sawhney, A. (2026). A Paradigm Shift in Respiratory Syncytial Virus Prevention in Infants. A Paradigm Shift in Respiratory Syncytial Virus Prevention in Infants, III(02). https://doi.org/10.62830/mmj3-02-6a
Vancouver
Sawhney A. A Paradigm Shift in Respiratory Syncytial Virus Prevention in Infants. A Paradigm Shift in Respiratory Syncytial Virus Prevention in Infants. 2026;III(02). doi:10.62830/mmj3-02-6a
BibTeX
@article{Sawhney2026,
author = {Sawhney, Ashu},
title = {A Paradigm Shift in Respiratory Syncytial Virus Prevention in Infants},
journal = {A Paradigm Shift in Respiratory Syncytial Virus Prevention in Infants},
year = {2026},
volume = {III},
number = {02},
doi = {10.62830/mmj3-02-6a}
}
EUVIMED